Atropos Health, a pioneer in transforming real-world clinical data into actionable real-world evidence (RWE), has announced a collaboration with Merck to accelerate evidence generation and analytics. Leveraging Atropos’ suite of tools, including GENEVA OS™, Green Button™, and ChatRWD™, the partnership will enable rapid cohort creation, advanced analytics, and publication-grade studies in less than 48 hours. Merck’s data science and RWE teams will collaborate closely with Atropos’ experts to produce fast, accurate insights that support decision-making and innovation.
Atropos Health provides access to the industry’s largest federated healthcare data network, with over 300 million patient records, ensuring partners can access fit-for-purpose real-world data (RWD) through tools like Alexandria™ and Forge™. These platforms allow users to replicate studies, generate novel insights, and accelerate research by transforming months-long processes into minutes with AI-driven solutions. Atropos also evaluates data quality with its Real World Fitness Score® for better reliability and relevance.
The announcement comes as Atropos continues to expand its generative AI capabilities, including the launch of ChatRWD™, which enables full observational studies in minutes. In May 2024, Atropos raised $33 million in funding led by Valtruis, with significant contributions from Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, to support its mission of revolutionizing health data analytics.
Click here to read the original news story.